OBJECTIVES This study performed a contemporary systematic review and meta-analysis of exercise-based cardiac rehabilitation (ExCR) for heart failure (HF).
C hronic heart failure (HF) represents a major health issue that affects 1% to 2% of adults in the Western world (1, 2) . Whereas survival after HF diagnosis has improved, prognosis remains poor; 30% to 40% of patients die within 1 year of diagnosis (1, 2) . Patients living with HF experience marked reductions in their exercise capacity, which has detrimental effects on their activities of daily living and health-related quality of life (HRQoL) (3, 4) .
Meta-analyses of randomized trials over the last decade support the Class I recommendation of current national and international clinical guidelines that exercise-based cardiac rehabilitation (ExCR) should be offered to all patients with HF (5) (6) (7) . However, the authors of the 2014 Cochrane ExCR review raised concerns about the generalizability of their meta-analysis results given that trial participants were predominantly lower-risk male patients who had HF with reduced ejection fraction (8) .
Furthermore, recent surveys show that <10% of patients with HF in the United States and <20% in Europe participated in ExCR (9, 10) , prompting a call to explore more accessible alternatives to the conventional model of group supervised center-based ExCR, such as home-based and internet programs (8, 9) .
The present study undertook a review and metaanalyses of an updated Cochrane database in order to reassess the evidence base for ExCR in patients with HF, including recently performed randomized clinical trials. The updated review includes analysis of center-based compared to home-based programs.
This update incorporates both a formal assessment of overall trial quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines and trial sequential analysis (TSA) to control for type I and type II errors of conventional meta-analysis methods (11) .
METHODS
This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Cochrane Review Update: Rehabilitation for Heart Failure A U G U S T 2 0 1 9 : 6 9 1 -7 0 5 statement and the Cochrane Handbook for Interventional Reviews (12) (13) (14) . DATA Given the relatively small trial-to-covariate ratio, metaregression was limited to univariate analysis (14) . This study sought to explore small-study bias and the potential for publication bias by using funnel Figure 1 . Four trials (18) (19) (20) (21) included more than 1 comparison between patients with ExCR and control subjects, resulting in a total of 48 ExCR-versus-control comparisons.
STUDY, PATIENT, AND INTERVENTION CHARACTERISTICS.
The included trials randomized a total of 5,783 patients, predominantly those with HF with reduced ejection fraction and New York Heart Association functional classes II and III ( Table 1) . Eight trials formally stated that they included patients with HF with preserved ejection fraction (defined as either an ejection fraction of >40% or a diagnosis of diastolic HF) (18, (22) (23) (24) (25) (26) (27) (28) . The median follow-up was 6 months, and 6 studies reported $12 months of follow-up. Most studies were small in sample size (median: n ¼ 52), with 1 large multicenter trial (HF-ACTION) (17) contributing w40% of all participants. The median age of participants across studies was 63 years old.
Although 33 studies (75%) included women, the median proportion of women recruited was only 19%.
More recent studies (published from 2013 to 2018) were more likely to recruit participants who were older, female, and had HF with preserved ejection fraction.
ExCR programs were typically delivered in a supervised hospital or center-based setting, either exclusively or in combination with some maintenance home-exercise sessions. Nine studies were conducted in an exclusively home-based setting (18, 20, 24, (28) (29) (30) (31) (32) (33) (34) . Table 2) . However, the other 5 items (incomplete outcome data, selective reporting, groups balanced at baseline, intention-to-treat analysis conducted, and groups who received the same treatment apart from the ExCR intervention) were generally judged to be at low risk of bias. There was no *Some concerns arose with random sequence generation and allocation concealment; bias likely, therefore the quality of evidence was downgraded by 1 level. †Imprecise due to small numbers of events (<300); therefore, certainty of evidence was downgraded by 1 level. ‡Some concerns appeared with random sequence generation, allocation concealment, and blinding of outcome assessment; bias likely, therefore, certainty of evidence was downgraded by 1 level. kInconsistent directions of effect and substantial statistical heterogeneity (I 2 ¼ 66%); therefore, certainty of evidence was downgraded by 1 level. ¶Imprecise due to confidence intervals, including potential for no benefit and important benefit, as 95% CI crosses RR of 0.75; therefore, certainty of evidence was downgraded by 1 level.
#Inconsistency with considerable statistical heterogeneity (I 2 ¼ 82%); therefore, certainty of evidence was downgraded by 1 level. **Inconsistency with considerable statistical heterogeneity (I 2 ¼ 87%); therefore, certainty of evidence was downgraded by 1 level. † †Inconsistency with substantial statistical heterogeneity (I 2 ¼ 73%); therefore, certainty of evidence was downgraded by 1 level. § §Imprecise due to small number of participants (<400); therefore, certainty of evidence was downgraded by 1 level. ***Some concerns with random sequence generation, allocation concealment, and groups balanced at baseline; bias likely, therefore, Taylor et al.
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Cochrane Review Update: Rehabilitation for Heart Failure ExCR versus control did not affect mortality with At 20% RRR, the TSA-adjusted CI was 0.54 to 0.92 for all-cause hospitalization up to 12 months, 0.14 to 2.46 for all-cause hospitalization >12 months, and 0.14 to 3.56 for HF-specific hospitalization (Online Table 3 , Online Figures 1.3c, 1.4c, and 1.5c ). This effect was lost when limited to trials at low risk of bias (Online Figure 1.3e) . mean difference: À7.1; 95% CI: À10.5 to À3.7) (very low certainty) ( Figure 2F ). An improvement in MLWHF score was also seen in the 3 trials (329 patients) that reported total MLWHF score beyond 12 months followup (random effects mean difference: À9.5;
95% CI: À17.5 to À1.5) (low certainty) ( Figure 2H) .
Pooling studies regardless of outcome measurement used showed that there may be a significant improvement in HRQoL with exercise at #12 months follow-up (random effects, 26 trials, 29 comparisons,
3,833 patients: standardized mean difference
[SMD]: À0.60; 95% CI: À0.82 to À0.39) (GRADE: very low certainty) ( Figure 2G) . GRADE rating was downgrading due to high risk of bias and inconsistency.
For MLWHF up to 12 months follow-up, the TSAadjusted CI was À13.2 to À1.0 and À42.10 to 23.12 for trials with longer follow-up (Online Table 3 , Online Figures 1.6b and 1.8a) . Across all HRQoL outcomes with conversion to MLWHF, mean difference: À1.7;
95% CI: À9.3 to À4.9 and TSA-adjusted CI was À9.9
to À4.3 (Online Figure 1.7b) . Although the MLWHF effect estimate of À7.1 favors ExCR and is larger than the minimal important clinical difference of 5 points, METAREGRESSION. There were no differential treatment effects across trial level characteristics and outcomes in univariate metaregression, except for the overall level of risk of bias and all-cause hospitalization, MLWHF, and HRQoL outcomes ( 95% CI: À8.0 to À1.9; vs. mean difference: À15.0;
95% CI: À17.8 to À12.3), and all HRQoL (SMD: À1.00;
95% CI: À1.33 to À0.66; vs. SMD: À0.48;
95% CI: À0.70 to À0.27).
SMALL STUDY BIAS. There was no evidence of funnel plot asymmetry, expect for all HRQoL measurements (Egger test p value <0.0001) (Online Figure 2 ). This asymmetry appeared to be due to an absence of small-to medium-sized studies with poorer HRQoL results for ExCR.
DISCUSSION
An updated systematic review and meta-analysis of ExCR was conducted in adults with HF. This study shows that, compared with no exercise control, ExCR does not appear to reduce or increase mortality. However, some of these outcome results are based on low GRADE rating evidence and may be prone to bias.
The TSA showed that for all clinical event outcomes, the second was that many included trials did not collect patient data for the time-to-event outcomes (35) . The present findings are consistent with those of other systematic reviews and meta-analyses of randomized controlled trials (RCTs) of CR for HF 
